Last reviewed · How we verify
Adalimumab, etanercept, infliximab
These are TNF-alpha inhibitors that block tumor necrosis factor-alpha, a key inflammatory cytokine driving immune-mediated diseases.
These are TNF-alpha inhibitors that block tumor necrosis factor-alpha, a key inflammatory cytokine driving immune-mediated diseases. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
At a glance
| Generic name | Adalimumab, etanercept, infliximab |
|---|---|
| Sponsor | University of Padova |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha (tumor necrosis factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Adalimumab, etanercept, and infliximab are three distinct TNF-alpha inhibitors used to suppress excessive TNF-alpha signaling in autoimmune and inflammatory conditions. Adalimumab is a fully human monoclonal antibody; etanercept is a TNF receptor fusion protein; infliximab is a chimeric monoclonal antibody. All three reduce TNF-alpha-driven inflammation and immune activation.
Approved indications
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Crohn's disease
- Ulcerative colitis
- Psoriasis
- Juvenile idiopathic arthritis
Common side effects
- Infections (including serious infections)
- Injection site reactions
- Upper respiratory tract infection
- Headache
- Tuberculosis reactivation
- Malignancy risk
Key clinical trials
- Psoriasis Longitudinal Assessment and Registry
- Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis (PHASE4)
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis (PHASE4)
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response (PHASE3)
- Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (NA)
- Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adalimumab, etanercept, infliximab CI brief — competitive landscape report
- Adalimumab, etanercept, infliximab updates RSS · CI watch RSS
- University of Padova portfolio CI